Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $22.4 million.

  • Barinthus Biotherapeutics' Non-Current Assets fell 5850.84% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.3 million, marking a year-over-year decrease of 4693.19%. This contributed to the annual value of $34.6 million for FY2024, which is 3995.76% down from last year.
  • According to the latest figures from Q3 2025, Barinthus Biotherapeutics' Non-Current Assets is $22.4 million, which was down 5850.84% from $29.1 million recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Non-Current Assets peaked at $61.4 million during Q2 2023, and registered a low of $3.1 million during Q2 2021.
  • For the 5-year period, Barinthus Biotherapeutics' Non-Current Assets averaged around $43.2 million, with its median value being $54.9 million (2024).
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 185117.54% in 2021, then tumbled by 5850.84% in 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Non-Current Assets (Quarter) stood at $54.0 million in 2021, then increased by 5.96% to $57.2 million in 2022, then rose by 0.76% to $57.6 million in 2023, then crashed by 39.96% to $34.6 million in 2024, then tumbled by 35.17% to $22.4 million in 2025.
  • Its Non-Current Assets stands at $22.4 million for Q3 2025, versus $29.1 million for Q2 2025 and $32.1 million for Q1 2025.